Respreeza: Clinical Trials

2 completed, 1 recruiting, 1 terminated. 2 Phase 2, 2 Phase 4, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	2	Completed 1, Terminated 1
Phase 4	2	Completed 1, Recruiting 1
Phase 3	1	Terminated 1

Follow Respreeza: new trials by email Literature Review of Respreeza trials Research Report on Respreeza

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) CE1226 - Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency	Phase 4	Recruiting	CSL Behring	270	2026-09-29	2026-10-16
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema SAR447537, Zemaira - Alpha 1-Antitrypsin Deficiency, Emphysema	Phase 2	Completed	Sanofi	99	2023-10-12	2025-08-11
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease	Phase 2 / Phase 3	Terminated	CSL Behring	222	2019-03-27	2026-09-09
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency. Alpha1- proteinase inhibitor [human] - Emphysema, Alpha 1-proteinase Inhibitor Deficiency	Phase 4	Completed	CSL Behring	140	2008-04-01	2016-08-15

Conditions studied

Emphysema (3)  ·  alpha 1-Antitrypsin Deficiency (3)

Sponsors

CSL Behring (3)  ·  Sanofi (1)

Countries

Australia (3)  ·  Denmark (3)  ·  Germany (2)  ·  Poland (2)  ·  Spain (2)  ·  Sweden (2)  ·  United States (2)  ·  Canada (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Finland (1)  ·  Ireland (1)  ·  Italy (1)  ·  Japan (1)  ·  New Zealand (1)

Results publications

PMID 26026936, PMID 27916480, PMID 30237305

NIH funding

2018 (1), 2023 (1), 2025 (1)